ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2007
Cancer epidemiology: study designs and data analysis.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Population Health OutcomEs aNd Information EXchange (PHOENIX) Program - A Transformative Approach to Reduce the Burden of Chronic Disease.Online journal of public health informatics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the scientific interests of cancer epidemiology is the identification of both environmental and genetic factors associated with cancer development. Observational designs requiring sophisticated methodology are applied to control for potential confounding factors. The enormous biotechnological potential developed in the last two decades has allowed the integration of a plethora of new biomarkers in epidemiological studies to better define the exposure and "neoclassic" outcomes, as well as incorporating genetic susceptibility factors in both classical and new epidemiological designs. The integration of scopes, objectives, data and tools coming from different disciplines also benefits epidemiology, thus evolving into "systems epidemiology". In this manuscript, we review the basic concepts of study designs and data analysis and introduce readers to the more innovative aspects that are now being applied in epidemiological studies.
Indexed as
Identifiers
17525039What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.